Aquestive Therapeutics (NASDAQ:AQST) Q3 2026 Revenue Miss Weighs on Shares Despite Anaphylm Progress
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug
Loading...